
Opinion|Videos|April 1, 2024
Addressing Risks and Challenges in the Standard of Care for Patients with nmCRPC
Neal Shore, MD, FACS provides an analysis of the ARAMIS, SPARTAN, and PROSPER trials, which demonstrate improved survival in high-risk non-metastatic castration-resistant prostate cancer through early intervention, highlighting the potential for preventing disease progression based on the data from these pivotal studies.
Advertisement
Episodes in this series

Advertisement
Related to this article

Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC
2
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
3
Crossover to Bezuclastinib Plus Sunitinib Improves Disease Control in Pretreated GIST
4
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
5
